## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3785000

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

#### **CONVEYING PARTY DATA**

Name	Execution Date
NEKTAR THERAPEUTICS	01/26/2016

#### **RECEIVING PARTY DATA**

Name:	TC LENDING, LLC, AS A COLLATERAL AGENT	
Street Address:	301 COMMERCE STREET	
Internal Address:	SUITE 3300	
City:	FORT WORTH	
State/Country:	TEXAS	
Postal Code:	76102	

#### **PROPERTY NUMBERS Total: 19**

Property Type	Number
Application Number:	14430587
Application Number:	14816975
Application Number:	14842464
Application Number:	14865362
Application Number:	62239207
Application Number:	14882265
Application Number:	14920554
Application Number:	14948976
Application Number:	14951035
Application Number:	14951197
Application Number:	14951105
Application Number:	14952172
Application Number:	14959538
Application Number:	14959604
Application Number:	14963000
Application Number:	14964416
Application Number:	14975381
Application Number:	14900039
Application Number:	14996801

PATENT REEL: 037990 FRAME: 0511

503738357

**CORRESPONDENCE DATA** 

**Fax Number:** (415)339-5323

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: atran@nektar.com

Correspondent Name: NEKTAR THERAPEUTICS

Address Line 1: 455 MISSION BOULEVARD SOUTH

Address Line 2: SUITE 100

Address Line 4: SAN FRANCISCO, CALIFORNIA 94158

NAME OF SUBMITTER:	MARK A. WILSON
SIGNATURE:	/Mark A. Wilson/
DATE SIGNED:	03/15/2016

#### **Total Attachments: 5**

source=US Security Grant January 2016 Supplement#page1.tif

source=US Security Grant January 2016 Supplement#page2.tif

source=US Security Grant January 2016 Supplement#page3.tif

source=US Security Grant January 2016 Supplement#page4.tif

source=US Security Grant January 2016 Supplement#page5.tif

# GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS

FOR GOOD AND VALUABLE CONSIDERATION, receipt and sufficiency of which are hereby acknowledged, Nektar Therapeutics, a Delaware corporation (the "Grantor") with principal offices at 455 Mission Bay Blvd South, Suite 100, San Francisco, CA 94158, hereby grants to TC Lending, LLC, as Collateral Agent, with principal offices at 301 Commerce Street, Suite 3300, Fort Worth, TX 76102, (the "Grantee"), a continuing security interest in (i) all of the Grantor's rights, title and interest in, to and under the United States patents (the "Patents") set forth on Schedule A attached hereto, in each case together with (ii) all proceeds (as such term is defined in the Uniform Commercial Code of the State of New York as in effect from time to time) and products of the Patents, and (iii) all causes of action arising prior to or after the date hereof for infringement of any of the Patents or unfair competition regarding the same.

THIS GRANT is made to secure the satisfactory performance and payment of all the Obligations of the Grantor, as such term is defined in the Pledge and Security Agreement among the Grantor, the other Grantors from time to time party thereto and the Grantee, dated as of October 5, 2015 (as amended, modified, restated and/or supplemented from time to time, the "Security Agreement"). Upon the occurrence of the Termination Date (as defined in the Security Agreement), the Grantee shall execute, acknowledge, and deliver to the Grantor an instrument in writing releasing the security interest in the Patents acquired under this Grant.

THIS GRANT has been granted in conjunction with the security interest granted to the Grantee under the Security Agreement. The rights and remedies of the Grantee with respect to the security interest granted herein are as set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

### SCHEDULE A)

тitle	Serial No.	Filing Date
METHODS AND SYSTEMS FOR IDENTIFYING DRY NEBULIZER ELEMENTS	14/430,587	03/23/2015
VIBRATION SYSTEMS AND METHODS	14/816,975	08/03/2015
SYSTEMS AND METHODS FOR DRIVING SEALED NEBULIZERS	14/842,464	09/01/2015
N-MALEIMIDYL POLYMER DERIVATIVES	14/865,362	09/25/2015
COMBINATION OF AN IL-2RBETA- SELECTIVE AGONIST AND A LONG- ACTING IL-15 AGONIST	62/239,207	10/08/2015
BRANCHED POLYMERS	14/882,265	10/13/2015
OLIGOMER-AMINO ACID CONJUGATES	14/920,554	10/22/2015
MULTI-ARM POLYMERIC ALKANOATE CONJUGATES	14/948,976	11/23/2015
POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD	14/951,035	11/24/2015
OLIGOMER-DIAROMATIC SUBSTITUTED CONJUGATES	14/951,197	11/24/2015
N-OPTIONALLY SUBSTITUTED ARYL-2- OLIGOMER-3-ALKOXYPROPIONAMIDES	14/951,105	11/24/2015
SALT FORM OF MULTI-ARM POLYMER- DRUG CONJUGATE	14/952,172	11/25/2015
OLIGOMER-OPIOID AGONIST CONJUGATES	14/959,538	12/04/2015
OLIGOMER-OPIOID AGONIST CONJUGATES	14/959,604	12/04/2015
OLIGOMER-BIS-CHROMONYL COMPOUND CONJUGATES	14/963,000	12/08/2015
POLYMER-FACTOR VIII MOIETY	14/964,416	12/09/2015

CONJUGATES	and the second s	And the control of th
AEROSOLIZATION DEVICE	14/975,381	12/18/2015
KAPPA OPIOID AGONISTS AND USES THEREOF	14/900,039	12/18/2015
OLIGOMER-SUBSTITUTED AROMATIC TRIAZINE CONJUGATES	14/996,801	01/15/2016

IN WITNESS WHEREOF, the undersigned have executed this Grant as of the Zarday of January, 2016.

NEKTAR THERAPEUTICS, Grantor

By:

Name: Gilbert M. Labrucherie, Jr.

Title: Senior Vice President and General Counsel

IN WITNESS WHEREOF, the undersigned have executed this Grant as of the day of Feloruary, 2016.

TC LENDING, LLC, as Collateral Agent and Grantee

By:

Title: Co-Chief Executive Officer

> **PATENT** REEL: 037990 FRAME: 0517

**RECORDED: 03/15/2016**